Interestingly, data from stage III unresectable non-small cell lung cancer (NSCLC) patients indicated that high TRAIL-Rs expression, specifically TRAIL-R2, positively correlated with increased risk of death [169]. Here, TNFRSF10B is linked to non-small cell lung carcinoma.